Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals


  • Products Id :- GDPH0476AD
  • |
  • Pages: 172
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2014. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the last five years.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 13

2 Pharmaceutical & Healthcare, Global, Deals Summary 18

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2014 18

2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2014 by Quarter 20

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2014 22

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2014 23

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2014 24

2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2014 25

2.5.1 Actavis Acquires Allergan for USD70.5 Billion 25

2.5.2 Medtronic Acquires Covidien for USD49.9 Billion 26

2.5.3 Actavis Completes Acquisition of Forest Labs for USD28 Billion 27

2.5.4 Sigma-Aldrich Receives Antitrust Approval for its Acquisition by Merck for USD17 Billion 29

2.5.5 Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 30

2.5.6 Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 31

2.5.7 GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 32

2.5.8 Merck Acquires Cubist Pharma for USD9.5 Billion 33

2.5.9 McKesson Completes Acquisition Of Celesio For USD 8.49 Billion 33

2.5.10 Roche Completes Tender Offer to Acquire InterMune for USD8.3 Billion 35

3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2014 36

4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 37

4.1 Pharmaceuticals & Healthcare, Global, M&A, 2014 37

4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2014 by Quarter 38

4.1.2 Top M&A Deals in 2014 39

4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2014 40

4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2014 41

4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2014 by Quarter 42

4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2014 43

4.2.3 Top IPOs in 2014 44

4.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2014 45

4.2.5 Top Secondary Offerings in 2014 46

4.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2014 47

4.2.7 Top PIPE Deals in 2014 48

4.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2014 48

4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2014 50

4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2014 by Quarter 51

4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2014 52

4.3.3 Top Public Debt Offerings in 2014 53

4.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2014 54

4.3.5 Top Private Debt Placements in 2014 55

4.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2014 55

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2014 57

4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2014 by Quarter 58

4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2014 60

4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (USD m), 2014 61

4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (USD m), 2014 62

4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2014 63

4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (USD m), 2014 64

4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), 2014 65

4.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2014 66

4.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2014 67

4.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2014 67

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2014 68

4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2014 by Quarter 69

4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2014 70

4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (USD m), 2014 71

4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (USD m), 2014 72

4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), 2014 73

4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), 2014 74

4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), 2014 75

4.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2014 76

4.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2014 77

4.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2014 78

4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2014 79

4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2014 by Quarter 80

4.6.2 Top Private Equity Deals in 2014 81

4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2014 82

4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2014 83

4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2014 by Quarter 84

4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2014 85

4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2014 86

4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2014 87

4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 88

4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2014 89

4.7.7 Top Venture Financing Deals in 2014 90

5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 91

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2014 91

5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2014 by Quarter 93

5.1.2 Oncology-Deals of the Year 94

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2014 98

5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2014 by Quarter 100

5.2.2 Central Nervous System-Deals of the Year 101

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2014 104

5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2014 by Quarter 106

5.3.2 Infectious Disease-Deals of the Year 107

5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2014 111

5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2014 by Quarter 113

5.4.2 Immunology-Deals of the Year 114

5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2014 117

5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2014 by Quarter 119

5.5.2 Cardiovascular-Deals of the Year 120

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2014 123

5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2014 by Quarter 125

5.6.2 Metabolic Disorders-Deals of the Year 126

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2014 130

5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2014 by Quarter 132

5.7.2 Gastrointestinal-Deals of the Year 133

6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 137

6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2014 137

6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2014 by Quarter 139

6.1.2 North America-Deals of the Year 140

6.2 Pharmaceuticals & Healthcare, European Region Deals, 2014 145

6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2014 by Quarter 147

6.2.2 Europe-Deals of the Year 148

6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2014 152

6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2014 by Quarter 154

6.3.2 Asia-Pacific-Deals of the Year 155

6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2014 158

6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2014 by Quarter 160

6.4.2 Rest of the World-Deals of the Year 161

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 165

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2014 165

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2014 167

8 Further Information 169

8.1 Methodology 169

8.2 About GlobalData 170

8.3 Disclosure information 171

8.4 Disclaimer 171

1.2 List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (USD m), 2010- 2014 18

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 20

Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2014 22

Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2014 23

Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (USD m), 2010-2014 37

Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 38

Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, 2014 40

Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), 2010-2014 41

Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 42

Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (USD m), 2010-2014 43

Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (USD m), 2010-2014 45

Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (USD m), 2010-2014 47

Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 48

Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (USD m), 2010-2014 50

Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 51

Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (USD m), 2010-2014 52

Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (USD m), 2010-2014 54

Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 55

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), 2010-2014 57

Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 58

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2014 59

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 60

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (USD m), 2014 61

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), 2014 62

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2014 63

Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2014 64

Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), 2014 65

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), 2010-2014 68

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 69

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 70

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (USD m), 2014 71

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), 2014 72

Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2014 73

Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (USD m), 2014 74

Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (USD m), 2014 75

Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (USD m), 2010-2014 79

Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 80

Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, 2014 82

Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (USD m), 2010-2014 83

Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 84

Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2014 85

Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2014 86

Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, 2014 87

Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (USD m), 2014 89

Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), 2010-2014 91

Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 93

Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), 2014, 2010-2014 98

Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 100

Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (USD m), 2010-2014 104

Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 106

Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), 2010-2014 111

Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 113

Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), 2010-2014 117

Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 119

Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (USD m), 2010-2014 123

Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 125

Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 130

Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 132

Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (USD m), 2010-2014 137

Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 139

Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (USD m), 2010-2014 145

Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 147

Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (USD m), 2010-2014 152

Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 154

Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (USD m), 2010-2014 158

Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 160

Figure 67: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (USD m), 2014 165

Figure 68: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (USD m), 2014 167

1.1 List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 19

Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 21

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2014 23

Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2014 24

Table 5: Pharmaceuticals & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (USD m), 2014 36

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 38

Table 7: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 39

Table 8: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2014 39

Table 9: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, 2014 40

Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 42

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 43

Table 12: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 44

Table 13 Pharmaceuticals & Healthcare, Global, Top IPOs, 2014 44

Table 14: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 45

Table 15: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2014 46

Table 16: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 47

Table 17: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2014 48

Table 18: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), 2014 49

Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 51

Table 20: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 52

Table 21: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 53

Table 22: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2014 53

Table 23: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 54

Table 24: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2014 55

Table 25: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (USD m), 2014 56

Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), 2010-2014 58

Table 27: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 59

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 60

Table 29: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (USD m), 2014 61

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), 2014 62

Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2014 64

Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (USD m), 2014 66

Table 33: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (USD m), 2014 66

Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2014 67

Table 35: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2014 67

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 68

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 69

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (USD m), 2014 70

Table 39: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (USD m), 2014 71

Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (USD m), 2014 73

Table 41: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2013-Q4 2014 75

Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (USD m), 2014 76

Table 43: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (USD m), 2014 76

Table 44: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2014 77

Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2014 78

Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 80

Table 47: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 81

Table 48: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2014 81

Table 49: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), 2014 82

Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 84

Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 85

Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2014 87

Table 53: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), 2014 88

Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2014 88

Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (USD m), 2014 90

Table 56: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2014 90

Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 92

Table 58: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 94

Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 99

Table 60: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 101

Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 105

Table 62: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 107

Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 112

Table 64: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 114

Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 118

Table 66: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 120

Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 124

Table 68: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 126

Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), 2010-2014 131

Table 70: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q4 2014 133

Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 138

Table 72: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 140

Table 73: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 146

Table 74: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 148

Table 75: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 153

Table 76: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 155

Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (USD m), 2010-2014 159

Table 78: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (USD m), Q1 2014-Q4 2014 161

Table 79: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (USD m), 2014 166

Table 80: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (USD m), 2014 168

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license

Single User License
USD 3500 INR 228200
Site License
USD 7000 INR 456400
Corporate User License
USD 10500 INR 684600

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com